Loading clinical trials...
Loading clinical trials...
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Conditions
Interventions
Vortioxetine
Locations
78
United States
The University of Arizona Sarver Heart Center (SHC)
Tucson, Arizona, United States
Kansas University School of Medicine-Wichita
Wichita, Kansas, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry
Cleveland, Ohio, United States
MHAT Targovishte AD
Targovishte, Bulgaria
Diagnostic Consultative Center Mladost-M Varna OOD
Varna, Bulgaria
Start Date
August 17, 2016
Primary Completion Date
March 25, 2022
Completion Date
April 19, 2022
Last Updated
December 28, 2022
NCT05415397
NCT07059234
NCT06396312
NCT06136546
NCT06398496
NCT06417619
Lead Sponsor
H. Lundbeck A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions